Cancer, Genomics and Personalised Medicine
The Omics Era
New technologies in genomics, proteomics and metabolomics allows us to get closer to the promise of personalised medicine. This is very crucial in cancer treatment because the reported rate of failure for the initial drug choice is 75% (FDA, 2013).
Current gene panels being used in personalised medicine test limited sets of genes, do not account for gene-gene interactions or take normal tissue bias into account. Some researchers even argue that DNA tests are only pre-symptomatic and cannot be used in real-time personalisation of medicine.
RNA can be used to get functional and molecular signatures of cancer from a tumour sample. The measurement of approximately 45,000 data points specific to the patient’s tumor allows for the first time a truly personalized analysis of the molecular aberrations in the cancer tissue.
Personalised Cancer Solutions
APT’s genomic computational analysis platform, PeCaSo™, powers its tumour-sample-to-physician report service solution for both front-line and non-responding cancer patients through partnering hospitals in India. Bypassing the gene-size and drug-choice limitations of current genetic panels, APT operates on the whole genome to identify networks of genes that can be addressed by currently approved cancer and general drugs.
Any Cancer, Any Stage
Solid tumours & Leukemia
Multiple chemo & adjuvant options
Not just cancer-specific chemos but also non-chemo options
Adverse Drugs Indicated